Comparative Proteome Analysis Identified CD44 as a Possible Serum Marker for Docetaxel Resistance in Castration-Resistant Prostate Cancer

High serum CD44 levels may help identify docetaxel-resistant patients and may thereby help optimize clinical decision-making regarding type and timing of therapy for metastatic CRPC patients patients.